Probes and methods of imaging non-Hodgkins lymphoma
Embodiments of the present disclosure provide for labeled probes such as a 64 Cu-FN3 probe (FN3 refers to fibronectin type 3 domain); methods of making labeled probes; pharmaceutical compositions including labeled probes; methods of using labeled probes; methods of diagnosing, localizing, monitoring, and/or assessing non-Hodgkin's lymphoma, cancers, tumors, precancerous cells, and related biological events using labeled probes; kits for diagnosing, localizing, monitoring, and/or assessing non-Hodgkin's lymphoma, cancers, tumors, precancerous cells, and related biological events; and the like.
1. A method of diagnosing the presence of a non-Hodgkin's lymphoma in a subject, the method comprising:
administering to the subject a labeled probe with a sequence having SEQ. ID. NO.: 2 or SEQ. ID. NO.: 4, wherein the probe binds to a CD20 protein;
imaging at least a portion of the subject; and
detecting the labeled probe, wherein the location of the labeled probe corresponds to the location of the non-Hodgkin's lymphoma.
2. The method of claim 1 , wherein the labeled probe includes a metal selected from the group consisting of: 64 Cu, 89 Zr, 86 Y and 68 Ga, and is conjugated with the sequence.
3. The method of claim 2 , wherein the metal is conjugated to the sequence via a lysine amino acid or a N-terminus free amine site.
4. The method of claim 2 , wherein at least two metals are conjugated to the sequence.
5. The method of claim 2 , wherein the metal is conjugated to the sequence using a chelator selected from the group consisting of: DOTA, NOTA, EDTA, desferrioxamine (Df), DTPA, and TETA.
6. The method of claim 5 , wherein the metal is 64 Cu and the chelator is DOTA.
7. The method of claim 1 , wherein the metal is 64 Cu and is conjugated to the sequence via a lysine amino acid or a N-terminus free amine site.
8. A method of monitoring the progress of a non-Hodgkin's lymphoma in a subject, the method comprising:
administering to the subject a labeled probe with a sequence having SEQ. ID. NO.: 2 or SEQ. ID. NO.: 4, wherein the probe binds to a CD20 protein;
imaging at least a portion of the subject; and
detecting the labeled probe, wherein location of the labeled probe corresponds to the location of the non-Hodgkin's lymphoma, wherein the location is monitored.
9. The method of claim 8 , further comprising repeating the steps of claim 8 to monitor the location corresponding to the non-Hodgkin's lymphoma.
10. The method of claim 8 , wherein the labeled probe includes a metal selected from the group consisting of: 64 Cu, 89 Zr, 86 Y and 68 Ga, and is conjugated with the sequence.
11. The method of claim 10 , wherein the metal is conjugated to the sequence via a lysine amino acid or a N-terminus free amine site.
12. The method of claim 10 , wherein at least two metals are conjugated to the sequence.
13. The method of claim 10 , wherein the metal is conjugated to the sequence using a chelator selected from the group consisting of: DOTA, NOTA, EDTA, Df, DTPA, and TETA.
14. The method of claim 13 , wherein the metal is 64 Cu and the chelator is DOTA.
15. The method of claim 10 , wherein the metal is 64 Cu and is conjugated to the sequence via a lysine amino acid or a N-terminus free amine site.
16. The method of claim 1 , wherein the sequence is SEQ. ID. NO.: 2.
17. The method of claim 1 , wherein the sequence is SEQ. ID. NO.: 4.
18. The method of claim 8 , wherein the sequence is SEQ. ID. NO.: 2.
19. The method of claim 8 , wherein the sequence is SEQ. ID. NO.: 4.